Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 2Phase 3 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 12Colonic Neoplasms 4Stomach Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Squamous Cell Carcinoma of Head and Neck 1Neuropathy, Painful 1Neuralgia 1Malignant Solid Tumour 1Liver Neoplasms 1Esophageal Neoplasms 1Cold Hypersensitivity 1Carcinoma, Hepatocellular 1CRC 1Advanced Colorectal Cancer 1

Interventions

Gemcitabine 97130-nm albumin-bound paclitaxel 47Albumin-Bound Paclitaxel 36Oxaliplatin 27Fluorouracil 26Capecitabine 20Taxes 19Leucovorin 19pembrolizumab 18Cyclophosphamide 17Irinotecan 16Bevacizumab 12Nivolumab 11Cetuximab 11fludarabine 10Cisplatin 10durvalumab 8Radiotherapy 8spartalizumab 7aldesleukin 7Erlotinib Hydrochloride 7Drug Therapy 7avelumab 6Radiosurgery 6Paclitaxel 6irinotecan sucrosofate 5folfirinox 5Ipilimumab 5Injections 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Pancreatic Neoplasms × Folfox protocol × Clear all
NCT03666832 2022-06-15

MP-PDAC-01

Samsung Medical Center

Phase 1/2 Unknown
36 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01632306 2019-01-15

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company

Phase 1/2 Terminated
13 enrolled 12 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡